Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Nanotechnology is Scopus-indexed (Q1, CiteScore 9.1), WoS SCIE, DOAJ. Published by BioMed Central Ltd.
Checked against the index lists dated .
ISSN 1868-6958Verify ISSN ↗1868-6966Verify ISSN ↗
Publisher: BioMed Central Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmaceutical Science | 27 / 191 | 86th | Q1 |
| Oncology | 65 / 428 | 84th | Q1 |
| Physical and Theoretical Chemistry | 32 / 194 | 83rd | Q1 |
| Biomedical Engineering | 72 / 342 | 79th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2010–present, best quartile Q1, CiteScore 9.1.
Cancer Nanotechnology is Q1 in Pharmaceutical Science (rank 27 of 191), Q1 in Oncology (rank 65 of 428) and Q1 in Physical and Theoretical Chemistry (rank 32 of 194), by CiteScore 2025. It is ranked in 4 subject areas in all.
Cancer Nanotechnology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 9.1, which places it in quartile Q1 at the 86th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.849, quartile Q1, with an H-index of 46.
The publisher lists an article processing charge of about US$1,990 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Nanotechnology is published by BioMed Central Ltd. Its print ISSN is 1868-6958 and its online ISSN is 1868-6966.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Cancer Nanotechnology has an h-index of 51 and a 2-year mean of 6.48 citations per paper (OpenAlex). Its Scopus CiteScore is 9.1, quartile Q1. On 2-year citations it ranks #17 of 177 Scopus journals in Pharmaceutical Science.
Cancer Nanotechnology published 57 papers in 2025; its busiest recent year was 2023 with 85. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from China (45.8%), Iran (10.2%) and India (10%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 6 retracted papers are recorded (12.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.